BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

910 related articles for article (PubMed ID: 21398619)

  • 1. Long-term outcomes of invasive ipsilateral breast tumor recurrences after lumpectomy in NSABP B-17 and B-24 randomized clinical trials for DCIS.
    Wapnir IL; Dignam JJ; Fisher B; Mamounas EP; Anderson SJ; Julian TB; Land SR; Margolese RG; Swain SM; Costantino JP; Wolmark N
    J Natl Cancer Inst; 2011 Mar; 103(6):478-88. PubMed ID: 21398619
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tamoxifen, radiation therapy, or both for prevention of ipsilateral breast tumor recurrence after lumpectomy in women with invasive breast cancers of one centimeter or less.
    Fisher B; Bryant J; Dignam JJ; Wickerham DL; Mamounas EP; Fisher ER; Margolese RG; Nesbitt L; Paik S; Pisansky TM; Wolmark N;
    J Clin Oncol; 2002 Oct; 20(20):4141-9. PubMed ID: 12377957
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adjuvant tamoxifen reduces subsequent breast cancer in women with estrogen receptor-positive ductal carcinoma in situ: a study based on NSABP protocol B-24.
    Allred DC; Anderson SJ; Paik S; Wickerham DL; Nagtegaal ID; Swain SM; Mamounas EP; Julian TB; Geyer CE; Costantino JP; Land SR; Wolmark N
    J Clin Oncol; 2012 Apr; 30(12):1268-73. PubMed ID: 22393101
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic Factors for Local Control in Breast Cancer After Long-term Follow-up in the EORTC Boost vs No Boost Trial: A Randomized Clinical Trial.
    Vrieling C; van Werkhoven E; Maingon P; Poortmans P; Weltens C; Fourquet A; Schinagl D; Oei B; Rodenhuis CC; Horiot JC; Struikmans H; Van Limbergen E; Kirova Y; Elkhuizen P; Bongartz R; Miralbell R; Morgan DA; Dubois JB; Remouchamps V; Mirimanoff RO; Hart G; Collette S; Collette L; Bartelink H;
    JAMA Oncol; 2017 Jan; 3(1):42-48. PubMed ID: 27607734
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevention of invasive breast cancer in women with ductal carcinoma in situ: an update of the National Surgical Adjuvant Breast and Bowel Project experience.
    Fisher B; Land S; Mamounas E; Dignam J; Fisher ER; Wolmark N
    Semin Oncol; 2001 Aug; 28(4):400-18. PubMed ID: 11498833
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial.
    Fisher B; Dignam J; Wolmark N; Wickerham DL; Fisher ER; Mamounas E; Smith R; Begovic M; Dimitrov NV; Margolese RG; Kardinal CG; Kavanah MT; Fehrenbacher L; Oishi RH
    Lancet; 1999 Jun; 353(9169):1993-2000. PubMed ID: 10376613
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Re: Long-term outcomes of invasive ipsilateral breast tumor recurrences after lumpectomy in NSABP B-17 and B-24 randomized clinical trials for DCIS.
    Formenti SC; Arslan AA; Pike MC
    J Natl Cancer Inst; 2011 Nov; 103(22):1723. PubMed ID: 21969339
    [No Abstract]   [Full Text] [Related]  

  • 8. Factors associated with local recurrence and cause-specific survival in patients with ductal carcinoma in situ of the breast treated with breast-conserving therapy or mastectomy.
    Vargas C; Kestin L; Go N; Krauss D; Chen P; Goldstein N; Martinez A; Vicini FA
    Int J Radiat Oncol Biol Phys; 2005 Dec; 63(5):1514-21. PubMed ID: 16005576
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of ipsilateral breast tumor recurrence after breast-conserving surgery between ductal carcinoma in situ and invasive breast cancer.
    Choi YJ; Shin YD; Song YJ
    World J Surg Oncol; 2016 Apr; 14():126. PubMed ID: 27122132
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Findings from recent National Surgical Adjuvant Breast and Bowel Project adjuvant studies in stage I breast cancer.
    Fisher B; Jeong JH; Dignam J; Anderson S; Mamounas E; Wickerham DL; Wolmark N
    J Natl Cancer Inst Monogr; 2001; (30):62-6. PubMed ID: 11773294
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Radiotherapy and tamoxifen after breast-conserving surgery for DCIS.
    Cunnick GH; Mokbel K
    Int J Fertil Womens Med; 2004; 49(5):237-8. PubMed ID: 15633483
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Five year outcome of 145 patients with ductal carcinoma in situ (DCIS) after accelerated breast radiotherapy.
    Ciervide R; Dhage S; Guth A; Shapiro RL; Axelrod DM; Roses DF; Formenti SC
    Int J Radiat Oncol Biol Phys; 2012 Jun; 83(2):e159-64. PubMed ID: 22579378
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Radiotherapy versus low-dose tamoxifen following breast-conserving surgery for low-risk and estrogen receptor-positive breast ductal carcinoma in situ: an international open-label randomized non-inferiority trial (TBCC-ARO DCIS Trial).
    Kuo SH; Tseng LM; Chen ST; Sagara Y; Chang YC; Yeh HT; Kuo YL; Hung CC; Lu TP; Lee YH; Toi M; Huang CS
    BMC Cancer; 2023 Sep; 23(1):865. PubMed ID: 37710198
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term Survival Comparison of Repeated Breast-conserving Surgery Versus Mastectomy for Patients with DCIS with Ipsilateral Breast Tumor Recurrence: A Real-world Longitudinal Study.
    Li Q; Wang K; Yang L; Wu Q; Zhu W; Li Z; Shi Y; Zhang X; Li H
    Clin Breast Cancer; 2021 Aug; 21(4):360-372. PubMed ID: 33846099
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Benefit of low-dose tamoxifen in a large observational cohort of high risk ER positive breast DCIS.
    Guerrieri-Gonzaga A; Sestak I; Lazzeroni M; Serrano D; Rotmensz N; Cazzaniga M; Varricchio C; Pruneri G; Leonardi MC; Orecchia R; Galimberti V; Bonanni B; DeCensi A
    Int J Cancer; 2016 Nov; 139(9):2127-34. PubMed ID: 27381855
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Correlation of clinical and pathologic features with outcome in patients with ductal carcinoma in situ of the breast treated with breast-conserving surgery and radiotherapy.
    Rodrigues N; Carter D; Dillon D; Parisot N; Choi DH; Haffty BG
    Int J Radiat Oncol Biol Phys; 2002 Dec; 54(5):1331-5. PubMed ID: 12459354
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Delay in radiotherapy is associated with an increased risk of disease recurrence in women with ductal carcinoma in situ.
    Shurell E; Olcese C; Patil S; McCormick B; Van Zee KJ; Pilewskie ML
    Cancer; 2018 Jan; 124(1):46-54. PubMed ID: 28960259
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Postoperative Tamoxifen for ductal carcinoma in situ: Cochrane systematic review and meta-analysis.
    Staley H; McCallum I; Bruce J
    Breast; 2014 Oct; 23(5):546-51. PubMed ID: 25023044
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic Significance of Clinicopathologic Features in Patients With Breast Ductal Carcinoma-in-Situ Who Received Breast-Conserving Surgery.
    Kuo SH; Lo C; Chen YH; Lien HC; Kuo WH; Wang MY; Lee YH; Huang CS
    Clin Breast Cancer; 2018 Dec; 18(6):441-450.e2. PubMed ID: 29709458
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Endocrine Therapy for Ductal Carcinoma In Situ (DCIS) of the Breast with Breast Conserving Surgery (BCS) and Radiotherapy (RT): a Meta-Analysis.
    Yan Y; Zhang L; Tan L; Ma X; Zhang Y; Shao S; Liu J; Xue C; Li Z; Zhang X; Drokow EK; Shi X; Ren J
    Pathol Oncol Res; 2020 Jan; 26(1):521-531. PubMed ID: 30499075
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 46.